![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/pfizer-puts-20m-rights-lianbio-rsv-program-greater-china
https://www.competitionpolicyinternational.com/pfizer-completes-acquisition-of-reviral/
https://www.biopharmadive.com/news/pfizer-rsv-reviral-acquisition-virus-drug/621751/
https://www.clinicaltrialsarena.com/news/reviral-paediatric-trial-sisunatovir/
https://www.businesswire.com/news/home/20210616005103/en/ReViral-Announces-Positive-Recommendation-by-the-Data-Safety-Monitoring-Committee-to-Continue-the-Phase-2-Clinical-Study-of-Sisunatovir-for-Treatment-of-Respiratory-Syncytial-Virus-Infections-in-Hospitalized-Infants
https://www.businesswire.com/news/home/20210302005084/en/ReViral-and-LianBio-Announce-Exclusive-Collaboration-and-License-Agreement-to-Develop-and-Commercialize-Sisunatovir-in-China
https://www.businesswire.com/news/home/20200825005795/en/ReViral-Raises-44-Million-Series-Financing